Integration of molecular diagnostics with therapeutics: Implications for drug discovery and patient care

Expert Review of Molecular Diagnostics

Volumn 2, Issue 6, 2002, Pages 531-541

  Ross, Jeffrey S ^a,b   Ginsburg, Geoffrey S ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Molecular diagnostics; Molecular medicine; Personalized medicine; Pharmacogenomics; Toxicogenomics

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; HERCEPTEST; IMATINIB; TRASTUZUMAB;

CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG TOXICITY; GENETIC PREDISPOSITION; GENOMICS; HEART DISEASE; PATIENT CARE; PHARMACODYNAMICS; PHARMACOGENOMICS; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; BIOTRANSFORMATION; CASE MANAGEMENT; DNA MICROARRAY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SCREENING; FAMILIAL CANCER; FORECASTING; GENE EXPRESSION PROFILING; GENETICS; HUMAN; PHARMACOGENETICS;

BIOTRANSFORMATION; CASE MANAGEMENT; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FORECASTING; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASTIC SYNDROMES, HEREDITARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 1842848834     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.2.6.531     Document Type: Review

References (100)

1. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
2. O'Dwyer ME, Druker BJ. STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol. 1, 207-211 (2000).
3. Keesee SK. Molecular diagnostics: Impact upon cancer detection. Expert Rev. Mol. Diagn. 2, 91-92 (2002).
4. Poste G. Molecular diagnostics: A powerful new component of the healthcare value chain. Expert Rev. Mol. Diagn. 1, 1-5 (2001).
5. Leonard DG. The present and future of molecular diagnostics. Mol. Diagn. (1)6, 71-72 (2001).
6. Amos J, Patnaik M. Commercial molecular diagnostics in the US: The Human Genome Project to the clinical laboratory. Hum Mutat. 19, 324-333 (2002).
7. Bottles K. A revolution in genetics: Changing medicine, changing lives. Physician Exec. 27, 58-63 (2001).
8. Advance Tech Monitor (2001).
9. Bordet P, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur. J. Clin. Pharmacol. 56, 935-941 (2001).
10. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 34, 1373-1379 (2000).
11. du Souich P. In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? J. Clin. Pharmacol. 8, 153-161 (2001).
12. Ginsburg GS, McCarthy JJ. Personalized medicine: Revolutionizing drug discovery and patient care. Trends Biotechnol. 19, 491-496 (2001).
13. Ross JS, Fletcher JA. The HER-2/neu Oncogene in breast cancer: Prognostic factor, predictive factor and target for therapy. Oncologist 3, 237-252 (1998).
14. Morgan GJ, Pratt G. Modern molecular diagnostics and the management of haematological malignancies. Clin. Lab. Haematol. 20, 135-141 (1998).
15. Zareba. W, Moss AJ, Schwartz PJ et al. Influence of genotype on clinical course of the long-QT syndrome. N. Engl. J. Med. 339, 960-965 (1998).
16. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 as well as LQT3 models of the long-QT syndrome. Circulation 96, 2038-2047 (1997).
17. + channel blockade and to increases in heart rate: Implications for gene-specific therapy. Circulation 92, 3381-3386 (1995).
18. Jordan VC. Progress in the prevention of breast cancer: Concept to reality. J. Steroid Biochem. Mol. Biol. 74, 269-277 (2000).
19. Doren M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: Update on clinical trials since 1995. Hum Reprod. Update 6, 419-426 (2000).
20. Crouch MA. Effective use of statins to prevent coronary heart disease. Am. Fam. Physician 63, 309-320 (2001).
21. Taylor JG, Choi EH, Foster CB, Chanock SJ. Using genetic variation to study human disease. Trends Mol. Med. 7, 507-512 (2001).
22. Carlson CS, Newman TL, Nickerson DA. SNPing in the human genome. Curr. Opin. Chem. Biol. 5, 78-85 (2001).
23. Griffin TJ, Smith LM. Single-nucleotide polymorphism analysis by MALDI TOF mass spectrometry. Trends Biotechnol. 18, 77-84 (2000).
24. Kallioniemi OP. Biochip technologies in cancer research. Ann. Med. 33, 142-147 (2001). Overview of high-throughput microarrays and their potential clinical applications.
25. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev. Cancer 1, 99-108 (2001). Reviews the use of SNP detection and cancer therapy selection.
26. Borg A. Molecular and pathological characterization of inherited breast cancer. Semin. Cancer Biol. 11, 375-385 (2001).
27. x perspective. Expert Rev. Mol. Diagn. 1, 255-263 (2001).
28. Jass JR. Familial colorectal cancer: Pathology and molecular characteristics. Lancet Oncol. 1, 220-226 (2000).
29. Weber W, Estoppey J, Stoll H. Familial cancer diagnosis. Anticancer Res. 21, 3631-3635 (2001).
30. Calzone KA, Biesecker BB. Genetic testing for cancer predisposition. Cancer Nurs. 25, 15-25 (2002).
31. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat. Res. 482, 11-19 (2001).
32. Ingelman-Sundberg M. Pharmacogenetics: An opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250, 186-200 (2001).
33. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin. Chim. Acta. 315, 137-155 (2002).
34. Roses AD. Pharmacogenetics. Hum. Mol. Genet. 10, 2261-2267 (2001). Thorough review of SNP testing and predicting drug toxicity.
35. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fiuorouracil. Pharmacology 61, 199-203 (2000).
36. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev. Cancer 1, 99-108 (2001).
37. Linder MW, Valdes R Jr. Genetic mechanisms for variability in drug response and toxicity. J. Anal. Toxicol. 25, 405-413 (2001).
38. Danesi R, De Braud F, Fogli S, Di Paolo A, Del Tacca M. Pharmacogenetic determinants of anticancer drug activity and toxicity. Trends Pharmacol. Sci. 22, 420-426 (2001).
39. Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1, 65-70 (2001).
40. Durant J, Clevenbergh P, Halfon P et al. Drug resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 353, 2195-2199 (1999).
41. Rusnak JM, Kisabeth RM, Herbert DP, McNeil DM. Pharmacogenomics: A clinician's primer on emerging technologies for improved patient care. Mayo Clin. Proc. 76, 299-309 (2001).
42. Hess P, Cooper D. Impact of pharmacogenomics on the clinical laboratory. Mol. Diagn. 4, 289-298 (1999).
43. Harkin DP. Uncovering functionally relevant signaling pathways using microarray based expression profiling. Oncologist 5, 501-507 (2000).
44. Snijders AM, Meijer GA, Brakenhoff RH, van den Brule AJ, van Diest PJ. Microarray techniques in pathology: Tool or toy? Mol. Pathol. 53, 289-294 (2000).
45. Raetz EA, Moos PJ, Szabo A, Carroll WL. Gene expression profiling. Methods and clinical applications in oncology. Hematol. Oncol. Clin. North Am. 15, 911-930 (2001).
46. Polyak K, Riggins GJ. Gene discovery using the serial analysis of gene expression technique: Implications for cancer research. J. Clin. Oncol. 19, 2948-2958 (2001).
47. Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P. Unlocking the archive gene expression in paraffin-embedded tissue. J. Pathol. 195, 66-71 (2001).
48. Maughan NJ, Lewis FA, Smith V. An introduction to arrays. J. Pathol. 195, 3-6 (2001). Reviews the different types of microarrays.
49. Alizadeh AA, Ross DT, Perou CM, van de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. J. Pathol. 195, 41-52 (2001).
50. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J. Clin. Oncol. 20, 1932-1941 (2002). Considers the impact of tumor classification by gene expression profiling.
51. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470 (1995).
52. Zanders ED. Gene expression analysis as an aid to the identification of drug targets. Pharmacogenomics 1, 375-384 (2000). How companies are using transcriptional profiling to detect new drug targets.
53. Weinstein JN. Pharmacogenomics -teaching old drugs new tricks. N. Engl. J. Med. 343, 1408-1409 (2000). Basic primer on pharmacogenomics.
54. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 61, 199-203 (2000).
55. Los G, Yang F, Samimi G et al. Using mRNA expression profiling to determine anticancer drug efficacy. Cytometry 47, 66-71 (2002).
56. Slonim DK. Transcriptional profiling in cancer: The path to clinical pharmacogenomics. Pharmacogenomics 2, 123-136 (2001).
57. Dougherty ER, Barrera J, Brun M et al. Inference from clustering with application to gene-expression microarrays. J. Comput. Biol. 105-126 (2002).
58. Fryer RM, Randall J, Yoshida T et al. Global analysis of gene expression: Methods, interpretation and pitfalls. Exp. Nephrol. 10, 64-74 (2002).
59. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: Clinical application. Clin. Chem. 46, 673-683 (2000).
60. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 7, 9-16 (2002). The proteasome inhibitor PS-341 shows significant promise for the treatment of patients with multiple myeloma.
61. Elliott PJ, Ross JS. The proteasome: A new target for novel drug therapies. Am. J. Clin. Pathol. 116, 637-646 (2001).
62. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20, 110-124 (2002).
63. Hamadeh HK, Bushel P, Paules R, Afshari CA. Discovery in toxicology: Mediation by gene expression array technology. J. Biochem. Mol. Toxicol. 15, 231-242 (2001).
64. Fielden MR, Zacharewski TR. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol. Sci. 60, 6-10 (2001).
65. Burchiel SW, Knall CM, Davis JW 2nd, Paules RS, Boggs SE, Afshari CA. Analysis of genetic and epigenetic mechanisms of toxicity: Potential roles of toxicogenomics and proteomics in toxicology. Toxicol. Sci. 59, 193-195 (2001).
66. Hamadeh HK, Amin RP, Paules RS, Afshari CA. An overview of toxicogenomics. Curr. Issues Mol. Biol. 4, 45-56 (2002).
67. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA 97, 12329-12333 (2000).
68. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for Metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001). Original Herceptin clinical trial story.
69. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin. Breast Cancer 2, 129-135 (2001).
70. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8, S14-8 (2002). Most recently approved anticancer targeted therapy.
71. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Med Klin. 97(Suppl.) 1, 28-30 (2002).
72. Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: Small molecules, big hopes. J. Clin. Oncol. 20, 2217-2219 (2002).
73. Fox SB, Gasparini G, Harris AL. Angiogenesis: Pathological, prognostic and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2, 278-289 (2001).
74. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 29, 27-36 (2002).
75. McDevitt MR, Barendswaard E, Ma D et al. An α-particle emitting antibody ([213BI ] J 591]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 60, 6095-6100 (2000).
76. Sievers EL, Linenberger M. Mylotarg: Antibody-targeted chemotherapy comes of age. Curr. Opin. Oncol. 13, 522-527 (2001).
77. Piecyk M, Anderson P. Signal transduction in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 15, 789-803 (2001).
78. Williamson AA, McColl GJ. Early rheumatoid arthritis: Can we predict its outcome? Intern. Med. J. 31, 168-180 (2001).
79. Watts DA, Satsangi J. The genetic jigsaw of inflammatory bowel disease. Gut 50(Suppl.3), 31-36 (2002).
80. Satsangi J. Genetics of inflammatory bowel disease: From bench to bedside? Acta Odontol. Scand. 59, 187-192 (2001).
81. Parel VB, Robbins MA, Topol EJ. C-reactive protein: A 'golden marker' for inflammation and coronary artery disease. Cleveland Clin. J. Med. 68, 521-524 (2001).
82. Feinstein SB, Voci P, Pizzuto F. Noninvasive surrogate markers of atherosclerosis. Am J. Cardiol. 89(5A), 31C-43C (2002).
83. Stein E. Laboratory surrogates for anti-atherosclerotic drug development. Am. J. CardioL 87(4A), 21A-26A (2001).
84. McCarthy MI, Hattersley AT. Molecular diagnostics in monogenic and multifactorial forms of Type 2 diabetes. Expert Rev. Mol. Diagn. 1, 403-412 (2001).
85. Berger A, Preiser W. Viral genome quantification as a tool for improving patient management: The example of HIV, HBV, HCV and CMV. J. Antimicrob. Chemother. 49, 713-721 (2002).
86. Vandamme AM, Houyez F, Banhegyi D et al. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir. Ther. 6, 21-39 (2001).
87. Buss N, Cammack N. Measuring the effectiveness of antiretroviral agents. Antivir. Ther. 6, 1-7 (2001). Retroviral therapy monitoring remains the most frequently utilized molecular diagnostic test yet discovered.
88. Russo A, Zanna I, Tubiolo C et al. Hereditary common cancers: Molecular and clinical genetics. Anticancer Res. 20, 4841-4851 (2001).
89. von Knebel Doeberitz M. New molecular tools for efficient screening of cervical cancer. Dis. Markers 17, 123-128 (2001).
90. Ross JS. Economic, regulatory and practice issues in molecular pathology and diagnostics. Am. J. Clin. Pathol. 112(Suppl. 1), S7-10 (1999).
91. Sakallah SA. Molecular diagnostics of infectious diseases: State of the technology. Biotechnol. Ann. Rev. 6, 141-161 (2000).
92. Pang CP. Molecular diagnostics for cardiovascular disease. Clin. Chem. Lab. Med. 36, 605-614 (1998).
93. Lacroix J, Doeberitz MK. Technical aspects of minimal residual disease detection in carcinoma patients. Semin. Surg. Oncol. 20, 252-264 (2001).
94. Morgan GJ, Pratt G. Modern molecular diagnostics and the management of haematological malignancies. Clin. Lab. Haematol. 20, 135-141 (1998).
95. Jain KK. Applications of proteomics in oncology. Pharmacogenomics 1, 385-393 (2000).
96. Lee KH. Proteomics: A technology-driven and technology-limited discovery science. Trends Biotechnol. 19, 217-222 (2001).
97. Herrmarnn PC, Liotta LA, Petricoin EF 3rd. Cancer proteomics: The state of the art. Dis. Markers 17, 49-57 (2001).
98. Srinivas PR, Srivastava S, Hanash S, Wright GL Jr. Proteomics in early detection of cancer. Clin. Chem. 47, 1901-1911 (2001).
99. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002). SELDI baroode proteomics detects 100% of Stage I ovarian cancer. If validated, this technique could 'revolutionize' molecular diagnostics.
100. Phelps ME. PET: The merging of biology and imaging into molecular imaging. J. Nucl. Med. 41, 661-681 (2000).